Akron Pharma Initiates Class III Recall of Diphenhydramine HCl 25 mg Capsules Due to Labeling Errors
Akron Pharma, Inc. has initiated a voluntary Class III recall of 456 bottles of Diphenhydramine HCl 25 mg capsules (Lot KDC0124002B) across the U.S. due to incorrect capsule imprints. This event highlights critical labeling compliance risks for procurement and regulatory teams, necessitating immediate review of supplier quality agreements and internal quality control processes to mitigate supply chain disruptions and ensure product integrity.
FDA-Initiated Class III Recall: Akron Pharma's Diphenhydramine HCl Labeling Discrepancy
Akron Pharma, Inc., based in Fairfield, NJ, has initiated a voluntary, firm-initiated Class III recall (D-0198-2025) for 456 bottles of its Diphenhydramine HCl 25 mg capsules. This recall, initiated on December 12, 2024, and classified by the FDA on January 10, 2025, stems from a critical labeling error where the tablets/capsules were imprinted with an incorrect identification code. The affected product, identified by NDC 71399-8028-2 and Lot KDC0124002B, has an expiration date of September 30, 2026, and was distributed nationwide across the United States. Each bottle contains 1000 capsules, making the total affected quantity significant for distributors and pharmacies relying on this specific lot. For procurement directors and supply chain VPs, this incident underscores the persistent risk of quality control failures even for widely used over-the-counter (OTC) medications. While a Class III recall indicates that the use of or exposure to the violative product is not likely to cause adverse health consequences, the reputational damage and logistical burden for distributors and retailers are tangible. Businesses must immediately verify their inventory against Lot KDC0124002B and quarantine any affected stock. Furthermore, this event necessitates a review of existing supplier quality agreements with Akron Pharma and other generic drug manufacturers to ensure robust label verification and quality assurance protocols are in place, preventing similar identification errors from impacting their downstream products and consumer trust.
Supply Chain Exposure and Commercial Implications for Diphenhydramine HCl Buyers
The nationwide distribution of Akron Pharma's recalled Diphenhydramine HCl 25 mg capsules means that pharmaceutical distributors, retail pharmacy chains, and potentially institutional buyers across the United States are directly impacted. Procurement teams must understand that even a Class III recall, which carries a lower health risk, can lead to significant commercial disruptions. The 456 bottles, each containing 1000 capsules, represent 456,000 individual doses that must be identified, returned, and replaced. This process incurs substantial costs related to reverse logistics, administrative overhead, and potential stock-outs if alternative supplies are not readily available. Regulatory affairs heads should note that while this was a firm-initiated voluntary recall, the FDA's classification and ongoing monitoring mean that Akron Pharma will be under increased scrutiny regarding its quality management systems. For businesses sourcing Diphenhydramine HCl, this event highlights the importance of diversifying their supplier base and not relying solely on a single manufacturer. A labeling error, though seemingly minor, points to potential weaknesses in a manufacturer's Good Manufacturing Practices (GMP) that could manifest in more severe issues in the future. Business development executives should assess how such recalls affect their market positioning and consider the competitive advantage of suppliers with impeccable regulatory compliance records.
Navigating Labeling Compliance Risks in Pharmaceutical Manufacturing
The core issue behind Akron Pharma's recall — tablets/capsules imprinted with the wrong identification code — points to a fundamental breakdown in labeling control within the manufacturing process. Accurate product identification is a cornerstone of pharmaceutical quality and patient safety, ensuring that the correct medication, dosage, and manufacturer are clearly discernible. This type of error can occur at various stages, from initial design and approval of imprint codes to the physical imprinting process and subsequent quality checks. For regulatory affairs and quality assurance teams, this incident serves as a critical reminder of the pervasive nature of labeling compliance challenges. Companies must implement rigorous, multi-layered verification processes for all product identification elements, including imprints, packaging labels, and associated documentation. This includes automated vision systems, manual checks, and robust change control procedures to prevent misprints or mislabeling. The financial and reputational costs associated with recalls, even for Class III events, far outweigh the investment in stringent quality control measures. Proactive engagement with contract manufacturing organizations (CMOs) and API suppliers to audit their labeling and packaging lines is essential. This ensures that all partners in the supply chain adhere to the highest standards, safeguarding against errors that could lead to costly recalls and erode market confidence.
Proactive Risk Mitigation Strategies for Pharmaceutical Procurement Teams
In light of Akron Pharma's Diphenhydramine HCl recall, procurement directors and supply chain VPs must implement enhanced risk mitigation strategies to protect their operations. The immediate action involves a thorough review of all current and prospective suppliers for Diphenhydramine HCl and similar generic drug products. This includes scrutinizing their FDA inspection history, recall records, and quality audit reports. While the Knowledge Graph does not provide alternative suppliers for Diphenhydramine HCl in this specific context, the principle remains: a diversified and thoroughly vetted supplier base is paramount. Develop robust supplier qualification programs that go beyond standard quality audits to specifically assess labeling and packaging control processes. This should include on-site audits focusing on imprint verification, line clearance procedures, and batch record reviews. Establish clear contractual clauses with suppliers regarding recall responsibilities, indemnification, and notification timelines. Furthermore, invest in real-time regulatory intelligence platforms to monitor supplier compliance and recall events proactively. This allows for rapid identification of potential supply chain vulnerabilities and enables swift action to secure alternative sources, minimizing the commercial impact of unforeseen regulatory actions like the Akron Pharma recall. This proactive stance ensures business continuity and protects your brand reputation in a highly regulated industry.
Broader Regulatory Landscape: Implications for Global Chemical and Life Sciences
The Akron Pharma recall, while specific to a labeling error for Diphenhydramine HCl, reflects a broader trend of heightened regulatory scrutiny on pharmaceutical quality control. The FDA continues to emphasize the importance of robust quality management systems across all aspects of drug manufacturing, from raw material sourcing to final product packaging. This vigilance extends beyond major drug recalls to include seemingly minor deviations, as evidenced by this Class III classification. For global chemical and life sciences companies, this means that every aspect of their product lifecycle, particularly in the highly regulated US market, is subject to intense oversight. Regulatory affairs heads must continuously monitor FDA guidance and enforcement trends, recognizing that issues like incorrect imprints can trigger recalls and potentially lead to more severe regulatory actions if systemic quality deficiencies are identified. This incident, alongside other recent parallel events such as Essential Wellness Pharma's Class II recall for sterility assurance failures, underscores the need for comprehensive quality systems that prevent a range of manufacturing and labeling defects. Business development executives should integrate regulatory compliance performance into their market entry and partnership strategies, as a strong compliance record is increasingly a competitive differentiator and a prerequisite for sustainable market access in the United States.